Gene Therapy for Brain-Destroying Lysosomal Diseases Is Finally Working

Neurometabolic lysosomal storage diseases (LSDs) are rare inherited disorders in which enzyme deficiencies allow toxic substrates to accumulate in the brain, causing relentless neurodegeneration. Conventional options — enzyme replacement therapy (ERT) and allogeneic hematopoietic stem cell transplantation (HSCT) — are substantially limited: ERT cannot cross the blood-brain barrier, and HSCT delivers only normal (not supranormal) enzyme levels while carrying transplant-related risks such as graft-versus-host disease and graft failure. A new generation of autologous HSPC-GT aims to overcome these barriers.

The HSPC-GT process involves mobilizing and collecting the patient's own CD34+ hematopoietic stem cells, transducing them ex vivo with a lentiviral vector encoding the corrective gene, and reinfusing them after myeloablative conditioning. Lentiviral vectors stably integrate into the stem cell genome, ensuring durable transgene expression in all hematopoietic progeny. Critically, HSPC-derived myeloid cells home to the brain and differentiate into microglia-like cells, providing a sustained local source of therapeutic enzyme that cross-corrects neighboring enzyme-deficient neurons and glia.

Clinical results across multiple diseases are encouraging. In MPS IH (Hurler syndrome), a Phase I/II trial of OTL-203 (LV-IDUA) showed supraphysiological blood IDUA activity, near-normalization of GAG excretion, detectable CSF enzyme activity, and stabilization of cognitive and motor function in 8 patients — outcomes exceeding those typically seen with HSCT. A Phase III randomized trial comparing OTL-203 to HSCT is now enrolling. For MPS II, a novel brain-targeted vector fusing IDS to ApoEII enhances blood-brain barrier transcytosis and achieved complete normalization of neuropathological deficits in mouse models; a Phase I/II human trial is underway at Manchester University. MPS IIIA trials using a myeloid-specific CD11b promoter-driven SGSH vector show supraphysiological enzyme expression and substrate reduction in plasma, CSF, and urine. For X-ALD, the Lenti-D (LV-ABCD1) product received FDA and EMA approval after Phase II/III data showed meaningful prevention of cerebral demyelination. For MLD, Libmeldy (LV-ARSA) achieved market authorization based on strong clinical stabilization data, representing the first approved gene therapy for a neurometabolic LSD.

Results in Fabry disease have been less durable, with enzyme levels declining over time due to suboptimal engraftment, leading the commercial sponsor to deprioritize the program. Pompe disease preclinical work is advancing using codon-optimized GAA sequences fused to IGF2 or glycosylation-independent lysosomal targeting tags to improve CNS penetration and glycogen clearance.

The field faces several ongoing challenges. Conditioning chemotherapy toxicity remains a concern, particularly in young or fragile patients. Long-term safety data on insertional mutagenesis from lentiviral integration are still being collected. Timing of treatment is critical — neurological benefit is greatest when therapy is initiated before symptomatic disease onset, making newborn screening programs essential. Cost and manufacturing complexity also pose access barriers. Nevertheless, the convergence of regulatory approvals, expanding trial portfolios, and improving vector engineering positions HSPC-GT as a potentially curative one-time intervention for a growing list of devastating neurometabolic diseases.